E. Karin Arkenbout

2.0k citations

34 papers · 1.4k indexed · 1 hit paper · h-index 19

Surgery top 5%
Cellular and Molecular Neuroscience top 5%
Cardiology and Cardiovascular Medicine top 5%
Immunology top 10%
Molecular Biology

Co-authors: Hans Pannekoek Carlie J.M. de Vries Robbert J. de Winter Karel T. Koch José P.S. Henriques Jan J. Piek Jan Baan Joanna J. Wykrzykowska
Topics: Coronary Interventions and Diagnostics (14 papers)Nuclear Receptors and Signaling (10 papers)Acute Myocardial Infarction Research (8 papers)
Cited by: Cellular and Molecular Neuroscience Cardiology and Cardiovascular Medicine Immunology
Journals: New England Journal of Medicine Circulation Blood
Partner nations: Netherlands United States Belgium

In The Last Decade

E. Karin Arkenbout

32 papers receiving 1.4k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Bioresorbable Scaffolds versus Metallic Stents in Routine PCI

2017 290 citations Joanna J. Wykrzykowska, Robin P. Kraak et al. New England Journal of Medicine profile →

Peers

Countries citing papers authored by E. Karin Arkenbout

Since Specialization

Citations

This map shows the geographic impact of E. Karin Arkenbout's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by E. Karin Arkenbout with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites E. Karin Arkenbout more than expected).

Fields of papers citing papers by E. Karin Arkenbout

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by E. Karin Arkenbout. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by E. Karin Arkenbout. The network helps show where E. Karin Arkenbout may publish in the future.

Co-authorship network of co-authors of E. Karin Arkenbout

This figure shows the co-authorship network connecting the top 25 collaborators of E. Karin Arkenbout. A scholar is included among the top collaborators of E. Karin Arkenbout based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with E. Karin Arkenbout. E. Karin Arkenbout is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Contemporary Use of Post‐Dilatation for Stent Optimization During Percutaneous Coronary Intervention; Results From the Netherlands Heart Registration 2025 ·Catheterization and Cardiovascular Interventions ·(unknown),Marijke Timmermans,(unknown),(unknown),Adriaan O. Kraaijeveld,E. Karin Arkenbout,Carl E. Schotborgh,(unknown),Bimmer E. Claessen,Eric Lipsic,Jawed Polad,Lokien X. van Nunen,Krischan D. Sjauw,Dennis van Veghel,Pim A.L. Tonino,Koen Teeuwen	0
2	Safety and feasibility of nationwide invasive coronary function testing in patients with angina and no obstructive coronary artery disease (NL-CFT) 2024 ·European Heart Journal ·(unknown),Tijn P.J. Jansen,Joan G. Meeder,(unknown),Martijn Meuwissen,(unknown),E. Karin Arkenbout,Pier Woudstra,Martin G. Stoel,(unknown),Jos Widdershoven,Hester M. den Ruijter,(unknown),Suzette Elias‐Smale,Peter Damman	1
3	Using Coronary Artery Calcium Score as Diagnostic Tool in Symptomatic Chronic Coronary Syndrome Patients in a Real-Life Setting 2023 ·Vascular Health and Risk Management ·M. Witvliet,E. Karin Arkenbout,Pieter W. Kamphuisen	1
4	Outcomes of bioresorbable vascular scaffolds versus everolimus-eluting stents by coronary complexity: a sub-analysis of the AIDA trial 2020 ·EuroIntervention ·Robin P. Kraak,R. Tijssen,(unknown),Joëlle Elias,Sjoerd H. Hofma,René J. van der Schaaf,E. Karin Arkenbout,(unknown),Jan G.P. Tijssen,Jan J. Piek,Robbert J. de Winter,José P.S. Henriques,Joanna J. Wykrzykowska	0
5	Three‐year clinical outcomes of the absorb bioresorbable vascular scaffold compared to Xience everolimus‐eluting stent in routine PCI in patients with diabetes mellitus— AIDA sub‐study 2020 ·Catheterization and Cardiovascular Interventions ·(unknown),R. Tijssen,Sjoerd H. Hofma,René J. van der Schaaf,E. Karin Arkenbout,(unknown),Robin P. Kraak,Yoshinobu Onuma,Patrick W. Serruys,Jan J. Piek,Jan G.P. Tijssen,José P.S. Henriques,Robbert J. de Winter,Joanna J. Wykrzykowska	2
6	A paradox in sex-specific clinical outcomes after bioresorbable scaffold implantation: 2-year results from the AIDA trial 2019 ·International Journal of Cardiology ·(unknown),R. Tijssen,Sjoerd H. Hofma,(unknown),Robin P. Kraak,Deborah N. Kalkman,René J. van der Schaaf,E. Karin Arkenbout,(unknown),Marcel A.M. Beijk,Jan Baan,Marije M. Vis,Karel T. Koch,Jan G.P. Tijssen,Jan J. Piek,José P.S. Henriques,Robbert J. de Winter,Joanna J. Wykrzykowska	1
7	Clinical outcomes at 2 years of the Absorb bioresorbable vascular scaffold versus the Xience drug‐eluting metallic stent in patients presenting with acute coronary syndrome versus stable coronary disease—AIDA trial substudy 2019 ·Catheterization and Cardiovascular Interventions ·R. Tijssen,René J. van der Schaaf,Robin P. Kraak,Maarten A. Vink,Sjoerd H. Hofma,E. Karin Arkenbout,(unknown),(unknown),Yoshinobu Onuma,Patrick W. Serruys,Marcel A.M. Beijk,Karel T. Koch,Jan Baan,Marije M. Vis,Jan J. Piek,Jan G.P. Tijssen,José P.S. Henriques,Robbert J. de Winter,Joanna J. Wykrzykowska	3
8	Complete two-year follow-up with formal non-inferiority testing on primary outcomes of the AIDA trial comparing the Absorb bioresorbable scaffold with the XIENCE drug-eluting metallic stent in routine PCI 2018 ·EuroIntervention ·R. Tijssen,Robin P. Kraak,Sjoerd H. Hofma,René J. van der Schaaf,E. Karin Arkenbout,(unknown),Joëlle Elias,(unknown),Karel T. Koch,Jan Baan,Marije M. Vis,Robbert J. de Winter,Jan J. Piek,Jan G.P. Tijssen,José P.S. Henriques,Joanna J. Wykrzykowska	20
9	A Randomized Comparison of Paclitaxel-Eluting Balloon Versus Everolimus-Eluting Stent for the Treatment of Any In-Stent Restenosis 2017 ·JACC: Cardiovascular Interventions ·Jan Baan,Bimmer E. Claessen,Kirsten Boerlage‐van Dijk,Jeroen Vendrik,René J. van der Schaaf,Martijn Meuwissen,Niels van Royen,A.T. Marcel Gosselink,Marleen van Wely,(unknown),E. Karin Arkenbout,Robbert J. de Winter,Karel T. Koch,Krischan D. Sjauw,Marcel A.M. Beijk,Marije M. Vis,Joanna J. Wykrzykowska,Jan J. Piek,Jan G.P. Tijssen,José P.S. Henriques	93
10	Bioresorbable Scaffolds versus Metallic Stents in Routine PCIbreakdown → 2017 ·New England Journal of Medicine ·Joanna J. Wykrzykowska,Robin P. Kraak,Sjoerd H. Hofma,René J. van der Schaaf,E. Karin Arkenbout,Alexander Ijsselmuiden,Joëlle Elias,(unknown),R. Tijssen,Karel T. Koch,Jan Baan,Marije M. Vis,Robbert J. de Winter,Jan J. Piek,Jan G.P. Tijssen,José P.S. Henriques	290
11	Initial experience and clinical evaluation of the Absorb bioresorbable vascular scaffold (BVS) in real-world practice: the AMC Single Centre Real World PCI Registry 2015 ·EuroIntervention ·Robin P. Kraak,Mariëlla E.C.J. Hassell,Maik J. Grundeken,Karel T. Koch,José P.S. Henriques,Jan J. Piek,Jan Baan,Marije M. Vis,E. Karin Arkenbout,Jan G.P. Tijssen,Robbert J. de Winter,Joanna J. Wykrzykowska	94
12	Orphan nuclear receptor Nur77 affects cardiomyocyte calcium homeostasis and adverse cardiac remodelling 2015 ·Scientific Reports ·Lejla Medzikovic,Cees A. Schumacher,Arie O. Verkerk,Elza D. van Deel,Rianne Wolswinkel,Ingeborg van der Made,(unknown),(unknown),Maarten M.G. van den Hoogenhof,Farid Meggouh,Esther E. Creemers,Carol Ann Remme,Antonius Baartscheer,Robbert J. de Winter,Carlie J.M. de Vries,E. Karin Arkenbout,Vivian de Waard	32
13	A Systematic Review and Meta-Analysis on Primary Percutaneous Coronary Intervention of an Unprotected Left Main Coronary Artery Culprit Lesion in the Setting of Acute Myocardial Infarction 2013 ·JACC: Cardiovascular Interventions ·Marije M. Vis,Marcel A.M. Beijk,Maik J. Grundeken,Jan Baan,Karel T. Koch,Joanna J. Wykrzykowska,E. Karin Arkenbout,Jan G.P. Tijssen,Robbert J. de Winter,Jan J. Piek,José P.S. Henriques	40
14	Amsterdam Investigator–initiateD Absorb strategy all-comers trial (AIDA trial): A clinical evaluation comparing the efficacy and performance of ABSORB everolimus-eluting bioresorbable vascular scaffold strategy vs the XIENCE family (XIENCE PRIME or XIENCE Xpedition) everolimus-eluting coronary stent strategy in the treatment of coronary lesions in consecutive all-comers: Rationale and study design 2013 ·American Heart Journal ·Pier Woudstra,Maik J. Grundeken,Robin P. Kraak,Mariëlla E.C.J. Hassell,E. Karin Arkenbout,Jan Baan,Marije M. Vis,Karel T. Koch,Jan G.P. Tijssen,Jan J. Piek,Robbert J. de Winter,José P.S. Henriques,Joanna J. Wykrzykowska	33
15	Six-month clinical outcomes of the Tryton Side Branch Stent for the treatment of bifurcation lesions 2012 ·Netherlands Heart Journal ·Maik J. Grundeken,M. Smits,Ralf E. Harskamp,Peter Damman,Pier Woudstra,(unknown),Jan Baan,E. Karin Arkenbout,Jan J. Piek,Marije M. Vis,José P.S. Henriques,K. T. Koch,Jan G.P. Tijssen,Robbert J. de Winter,Joanna J. Wykrzykowska	12
16	Degradation of the endothelial glycocalyx is associated with chylomicron leakage in mouse cremaster muscle microcirculation 2010 ·Thrombosis and Haemostasis ·(unknown),Jos A. E. Spaan,E. Karin Arkenbout,Hans Vink,Jurgen W. G. E. VanTeeffelen	24
17	Proteasome Inhibitors Enhance Endothelial Thrombomodulin Expression via Induction of Kruppel-Like Transcription Factors 2009 ·Arteriosclerosis Thrombosis and Vascular Biology ·Toyoko Hiroi,Clayton Deming,Haige Zhao,Baranda S. Hansen,E. Karin Arkenbout,Thomas J. Myers,Michael A. McDevitt,Jeffrey J. Rade	32
18	TR3 Nuclear Orphan Receptor Prevents Cyclic Stretch-Induced Proliferation of Venous Smooth Muscle Cells 2006 ·American Journal Of Pathology ·Vivian de Waard,E. Karin Arkenbout,Mariska Vos,(unknown),Hans W.M. Niessen,Wim Stooker,Bas A.J.M. de Mol,Paul H.A. Quax,Erik N.T.P. Bakker,Ed VanBavel,Hans Pannekoek,Carlie J.M. de Vries	57
19	Activin and TR3 orphan receptor: Two ‘atheroprotective’ genes as evidenced in dedicated mouse models 2003 ·Clinical and Experimental Pharmacology and Physiology ·Marten A. Engelse,E. Karin Arkenbout,Hans Pannekoek,(unknown)	8
20	Focusing on transcription factor families in atherogenesis: the function of LKLF and TR3 2003 ·Thrombosis and Haemostasis ·E. Karin Arkenbout,Rob J. Dekker,Carlie de Vries,Anton J.G. Horrevoets,Hans Pannekoek	10

About E. Karin Arkenbout

E. Karin Arkenbout is a scholar working on Cardiology and Cardiovascular Medicine, Cellular and Molecular Neuroscience and Surgery, having authored 34 papers that have together received 1.4k indexed citations. Recurring topics across this work include Coronary Interventions and Diagnostics (14 papers), Nuclear Receptors and Signaling (10 papers) and Acute Myocardial Infarction Research (8 papers). The work is most often cited by research in Cellular and Molecular Neuroscience (487 citations), Cardiology and Cardiovascular Medicine (482 citations) and Immunology (415 citations). E. Karin Arkenbout has collaborated with scholars based in Netherlands, United States and Belgium. Frequent co-authors include Hans Pannekoek, Carlie J.M. de Vries, Robbert J. de Winter, Karel T. Koch, José P.S. Henriques, Jan J. Piek, Jan Baan, Joanna J. Wykrzykowska, Marije M. Vis and Jan G.P. Tijssen. Their work appears in journals such as New England Journal of Medicine, Circulation and Blood.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact